SWM
APRE icon

Sugarloaf Wealth Management’s Aprea Therapeutics APRE Stock Holding History

Sugarloaf Wealth Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-750
Closed -$4.96K – 710
2022
Q4 		$4.96K Buy
750
+500
+200% +$5.28K ﹤0.01% 581
2022
Q3 		$4K Hold
250
– – ﹤0.01% 637
2022
Q2 		$4K Buy
250
+175
+233% +$4.03K ﹤0.01% 621
2022
Q1 		$3K Hold
75
– – ﹤0.01% 607
2021
Q4 		$4K Hold
75
– – ﹤0.01% 606
2021
Q3 		$8K Hold
75
– – ﹤0.01% 537
2021
Q2 		$7K Hold
75
– – ﹤0.01% 548
2021
Q1 		$8 Hold
75
– – ﹤0.01% 516
2020
Q4 		$7K Buy
+75
New +$35.7K ﹤0.01% 503

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Sugarloaf Wealth Management's APRE Position: Q1 2023 in Review

Sugarloaf Wealth Management sold out of Aprea Therapeutics (APRE) in Q1 2023, closing a stake of 750 shares — an estimated $4.96K sold.

Sugarloaf Wealth Management first reported a position in APRE in Q4 2020 and held it in 9 quarters. The position peaked at $8K in Q3 2021. 18 funds tracked by Wall St. Rank hold APRE as of Q1 2023.

  • Sugarloaf Wealth Management reported no remaining Aprea Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sugarloaf Wealth Management sold 750 Aprea Therapeutics shares in Q1 2023, an estimated $4.96K.
  • Sugarloaf Wealth Management first reported a position in Aprea Therapeutics in Q4 2020 and held it in 9 quarters.
  • Sugarloaf Wealth Management's Aprea Therapeutics position peaked at $8K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2023.

Based on Sugarloaf Wealth Management's 13F filing for Q1 2023, filed 26 Apr 2023.